Natural Management of Atopic Dermatitis
Evidence-based diet, gut health, and supplement approaches for reducing eczema flares and supporting skin barrier repair
Atopic dermatitis — commonly called eczema — is a chronic inflammatory skin condition affecting around 15–20% of children and 2–5% of adults worldwide. It involves a disrupted skin barrier, immune dysregulation, and a characteristic itch-scratch cycle that can significantly affect quality of life. While topical steroids and newer biologics are the conventional mainstays, a growing body of evidence supports gut health, specific nutrients, and barrier-repair strategies as meaningful complements that can reduce flare frequency and severity [2][3].
The Skin-Gut Connection
Eczema is not just a skin disease — it is significantly shaped by what happens in the gut. Research shows that infants and children with atopic dermatitis carry a distinct gut microbiome signature: reduced microbial diversity, lower levels of Bifidobacterium and Lactobacillus species, and increased abundance of pro-inflammatory microbes [2]. These imbalances appear early in life and track with disease severity.
The mechanism involves the gut-skin axis: gut dysbiosis compromises intestinal barrier integrity, allowing bacterial fragments to enter systemic circulation and trigger immune responses. The developing immune system in infants exposed to these signals is pushed toward a Th2-dominant, pro-allergic phenotype — the same immune skewing characteristic of eczema, asthma, and hay fever. See our Gut-Brain Axis page and Leaky Gut page for related context.
Probiotics: Prevention and Treatment
Probiotics have the most robust evidence of any natural intervention for atopic dermatitis, particularly for prevention in high-risk infants. A landmark randomized controlled trial by Kalliomäki et al. found that giving Lactobacillus rhamnosus GG to mothers during pregnancy and to their infants for the first six months of life halved the rate of eczema at two years of age (23% vs. 46% in placebo) [1]. The protective effect persisted at four and seven year follow-ups.
For treatment of established eczema, the evidence is more mixed. A systematic review found that roughly half of interventional probiotic trials showed meaningful improvements in SCORAD (eczema severity score), particularly with multi-strain formulations and Lactobacillus-dominant combinations [5]. The effect is most consistent in children under 12.
Practical guidance:
- For infant prevention in high-risk families, Lactobacillus rhamnosus GG supplementation in the last trimester and first 6 months of life is the best-evidenced strategy
- For treatment, multi-strain probiotics containing Lactobacillus and Bifidobacterium species, taken for at least 8 weeks, are more likely to be helpful than single-strain products
- Fermented foods — kefir, sauerkraut, live-culture yogurt — support microbial diversity alongside targeted supplementation
See our Probiotics page and Kefir page for more detail.
Vitamin D: Immune Regulator and Barrier Support
Low vitamin D levels are consistently associated with greater eczema severity across populations, and several trials have shown that supplementation reduces eczema scores, particularly in deficient individuals. A 2016 systematic review and meta-analysis of controlled trials concluded that vitamin D has a potentially significant role in improving atopic dermatitis symptoms and can be considered a safe, tolerable adjunct therapy [3].
Vitamin D supports eczema through multiple mechanisms: it stimulates production of antimicrobial peptides (cathelicidins) in skin cells, supports tight junction proteins that maintain the epidermal barrier, and shifts the immune system away from the Th2-dominant allergic phenotype toward a more balanced Th1/Treg profile.
Practical guidance:
- Have your 25-OH vitamin D level tested; levels below 30 ng/mL are common in eczema patients
- 1,000–2,000 IU/day for maintenance; 3,000–5,000 IU/day may be needed to correct deficiency (with K2 co-supplementation)
- Benefits are most evident in those who are deficient or in populations with limited sun exposure
See our Vitamin D page for general guidance.
Omega-3 Fatty Acids: Modulating the Inflammatory Response
EPA and DHA from fish oil compete with arachidonic acid in the inflammatory cascade, reducing production of pro-inflammatory prostaglandins and leukotrienes that drive eczema's itch and redness. An early double-blind trial found significant reductions in eczema scale, itch, and overall severity after 12 weeks of fish oil supplementation (10g/day, providing 3g n-3 fatty acids) compared to olive oil placebo [4].
More recent meta-analyses have produced mixed results, suggesting fish oil is most effective as part of a broader anti-inflammatory diet and nutritional approach rather than as a standalone therapy. The anti-inflammatory effect appears greater when baseline omega-6 intake is high — a common situation in Western diets rich in seed oils.
Practical guidance:
- 2–3g EPA+DHA daily; the evidence threshold appears to be at least 12 weeks
- Reducing omega-6 seed oils (sunflower, corn, soybean) while increasing omega-3s amplifies the effect
- Food sources with strong skin-related evidence: sardines, mackerel, wild salmon
See our Omega-3 page and Seed Oils page for more.
Skin Barrier Repair: Emollients and Moisturizers
Eczema-prone skin has structural defects in the epidermal barrier — mutations or variants in the filaggrin gene are present in around 30% of atopic dermatitis cases, and even without genetic defect, barrier function is compromised. Regular emollient use is the foundation of any eczema management plan, both for treatment and prevention of flares.
A Cochrane review of 77 randomized trials confirmed that emollients and moisturizers significantly reduce eczema severity, decrease the need for topical corticosteroids, and extend time between flares [6]. The exact formulation matters less than consistent, generous application — especially within minutes of bathing to trap moisture.
Natural emollient ingredients with evidence:
- Colloidal oatmeal: contains avenanthramides with anti-inflammatory and anti-itch properties; improves skin barrier, pH, and hydration
- Ceramides: restore the lipid lamellar structure of the stratum corneum; ceramide-dominant creams show measurable barrier improvement
- Sunflower seed oil and evening primrose oil: high in linoleic acid, which is low in eczema skin and needed for ceramide synthesis
Dietary Triggers and the Elimination Approach
Food allergy or sensitivity contributes to eczema flares in a subset of patients — most commonly in young children with moderate-to-severe disease. The most common dietary triggers are cow's milk, egg, wheat, soy, peanut, and tree nuts. However, food sensitivities in eczema are complex and not always IgE-mediated, making standard allergy testing unreliable as a guide.
A structured 2–4 week elimination trial, followed by systematic reintroduction, is the most informative approach. Key dietary shifts with broader evidence:
- Reduce ultra-processed foods: high sugar, refined carbohydrates, and seed oils worsen systemic inflammation
- Emphasize whole plant foods: diverse fiber supports the gut microbiome and Treg immune balance
- Breastfeeding: exclusive breastfeeding for at least 4–6 months is protective against eczema development
- Vitamin E and zinc: deficiencies of both are associated with increased eczema severity; whole food sources are generally preferable
Stress, Sleep, and the Itch-Scratch Cycle
Psychological stress reliably triggers and worsens eczema flares through cortisol-mediated disruption of the skin barrier and mast cell activation. Sleep deprivation compounds this by increasing inflammatory cytokines and lowering the itch threshold. Breaking the itch-scratch cycle through behavioral approaches — habit reversal training, scratch mitts at night — alongside stress management can measurably reduce severity.
Magnesium deficiency amplifies stress reactivity and can worsen itch sensitivity; transdermal magnesium via Epsom salt baths is anecdotally popular and may contribute to relaxation even if systemic absorption is modest.
See our Sleep page, Magnesium page, and Meditation and Breathwork page for supporting strategies.
Evidence Review
Probiotics and Primary Prevention of Atopic Dermatitis (Kalliomäki et al., 2001)
The Kalliomäki trial (PMID 11297958) is the foundational study in probiotic prevention of atopic disease. In this double-blind, randomized, placebo-controlled trial, 159 pregnant women with a personal or partner history of atopic disease were randomized to Lactobacillus rhamnosus GG (ATCC 53103, 1×10¹⁰ CFU twice daily) or placebo, starting 2–4 weeks before delivery. Infants also received the same preparation for the first 6 months of life. At age 2 years, atopic eczema was diagnosed in 23% of the probiotic group versus 46% of placebo (relative risk 0.51, 95% CI 0.32–0.84, p=0.0089). Follow-up at 4 years showed 14/53 children in the probiotic group had eczema versus 25/54 in placebo (RR 0.57, 95% CI 0.33–0.97). At 7 years, the cumulative risk reduction was sustained.
This study established the prenatal and early postnatal window as a critical period for microbiome-mediated immune programming. The effect size (roughly halving incidence) is clinically significant. Limitations include the relatively small sample size and single-strain design; meta-analyses suggest mixed strains may be more effective than LGG alone in some populations.
Strength of evidence: High for prevention in high-risk infants; moderate for treatment of established disease.
Gut-Skin Axis and Microbiome in Atopic Dermatitis (Lee et al., 2018)
Lee et al. (PMID 29949831) review the mechanistic evidence linking gut and skin microbiome dysbiosis to atopic dermatitis pathogenesis. In healthy skin, Staphylococcus epidermidis and other commensal species regulate immune tolerance. In eczema, Staphylococcus aureus overgrowth on the skin surface — present in up to 90% of atopic dermatitis patients during flares — releases proteases and toxins that directly damage the barrier and trigger Th2 cytokine release (IL-4, IL-13, IL-31). Simultaneously, gut microbial diversity is reduced, with loss of Bifidobacterium and Faecalibacterium prausnitzii — both producers of short-chain fatty acids that support regulatory T cell (Treg) induction.
The gut-skin axis operates through multiple interconnected pathways: systemic immune skewing toward Th2 driven by gut dysbiosis; reduced circulating SCFAs (especially butyrate) impairing skin barrier gene expression; and bacterial metabolites reaching skin via circulation and altering resident immune cell function. The review supports targeting gut microbiome composition as a strategy to modulate skin immune responses.
Strength of evidence: Strong mechanistic evidence; the axis itself is well-established. Specific therapeutic interventions targeting this axis (beyond general probiotic use) remain an active research area.
Role of the Gut Microbiota in Atopic Dermatitis: Systematic Review (Pedersen et al., 2018)
Pedersen et al. (PMID 30085318) systematically reviewed 44 studies (26 observational, 18 interventional) examining the relationship between gut microbiota and atopic dermatitis in Acta Dermato-Venereologica. Observational studies consistently showed reduced microbial diversity and altered bacterial composition in AD patients, with particularly consistent findings of reduced Bifidobacterium and Lactobacillus species. Among interventional studies examining probiotics, 9 of 18 (50%) demonstrated improvements in eczema severity scores. The studies with positive outcomes most commonly used multi-strain or Lactobacillus-dominant formulations, with treatment durations of 8–12 weeks or more.
The systematic review highlights an important limitation: many studies used different probiotic strains, doses, and outcome measures, making head-to-head comparisons difficult. It concludes that while the gut microbiota clearly plays a role in AD, the optimal probiotic intervention for established disease has not yet been definitively established.
Strength of evidence: Moderate. The evidence is directionally consistent for prevention; treatment evidence is promising but requires larger, more standardized trials.
Vitamin D and Atopic Dermatitis Meta-Analysis (Kim & Bae, 2016)
Kim and Bae (PMID 27061361) conducted a systematic review and meta-analysis of all controlled studies examining vitamin D in atopic dermatitis, published in Nutrition (2016). Analysis of controlled trials found that vitamin D supplementation was associated with significant improvement in eczema severity scores compared to placebo, with vitamin D3 outperforming vitamin D2 supplementation. The anti-eczema mechanisms of vitamin D are multifaceted: upregulation of antimicrobial peptide (cathelicidin/LL-37) production in keratinocytes directly combats S. aureus colonization; enhancement of tight junction proteins (claudin-1, filaggrin) restores barrier function; and vitamin D receptor signaling in T cells suppresses Th2 and Th17 cytokines while promoting Treg differentiation.
The authors note that studies in populations with confirmed vitamin D deficiency at baseline show the strongest therapeutic signal, while studies in vitamin D-replete populations are less consistent. This suggests that vitamin D supplementation is most valuable when correcting a genuine deficiency rather than as a universal therapy.
Strength of evidence: Moderate. Meta-analysis is limited by small individual trial sizes and heterogeneity in doses and populations. Subsequent larger trials (including PMID 39683522, 2024) continue to show benefit particularly in deficient subjects.
Omega-3 Fatty Acids in Atopic Dermatitis (Bjorneboe et al., 1989)
Bjorneboe et al. (PMID 2650695) conducted an early double-blind, placebo-controlled trial in which patients with atopic dermatitis received either 10g/day of fish oil (providing approximately 3g n-3 fatty acids) or olive oil placebo for 12 weeks. The fish oil group showed significantly greater improvements in eczema scale, itch, and overall severity ratings. This study established the mechanistic rationale: EPA supplementation reduces arachidonic acid availability, shifting prostaglandin and leukotriene synthesis away from the pro-inflammatory 2-series (PGE2, LTB4) toward the less inflammatory 3-series. LTB4 is a potent chemoattractant and activator of eosinophils and mast cells that drive eczema inflammation.
More recent larger trials and meta-analyses have been less consistent, showing modest or no effect at lower doses. A 2024 review (PMID 39772730) concluded that oral lipid supplementation can reduce eczema severity but that effect sizes are moderate and dose-dependent. The clinical picture is that omega-3s provide benefit as part of a comprehensive dietary strategy — particularly when omega-6 intake is simultaneously reduced — rather than as an isolated supplement.
Strength of evidence: Moderate. The mechanistic rationale is strong; clinical trial results are dose-dependent and context-sensitive. Most benefit is seen at higher doses (≥2g EPA+DHA/day) and in combination with dietary omega-6 reduction.
Emollients and Moisturizers for Eczema: Cochrane Review (van Zuuren et al., 2017)
Van Zuuren et al. (PMID 28166390) conducted a Cochrane systematic review analyzing 77 randomized controlled trials involving 6,603 participants to evaluate emollient effectiveness in atopic dermatitis. The review found high-quality evidence that regular emollient use significantly reduces eczema severity, decreases use of topical corticosteroids (which carries long-term risks with chronic use), increases time between flares, and improves patient-reported quality of life. No single emollient formulation was consistently superior; the key predictors of efficacy were regularity of application and adequate quantity (at least 250g/week in adults).
Ceramide-containing formulations showed particularly strong barrier-restoration effects in sub-group analyses. The review also found evidence that emollient use in the first weeks of life in high-risk neonates may delay or prevent eczema onset, though this requires confirmation in larger trials. Adverse events were rare and mild, confirming an excellent safety profile.
Strength of evidence: High. The Cochrane review includes multiple well-designed RCTs with consistent findings. Regular moisturizer use is the most evidence-supported non-pharmacological intervention for eczema management at any age.
References
- Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trialKalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. The Lancet, 2001. PubMed 11297958 →
- Microbiome in the gut-skin axis in atopic dermatitisLee SY, Lee E, Park YM, Hong SJ. Allergy, Asthma and Immunology Research, 2018. PubMed 29949831 →
- Vitamin D and atopic dermatitis: a systematic review and meta-analysisKim G, Bae JH. Nutrition, 2016. PubMed 27061361 →
- Effect of n-3 fatty acid supplement to patients with atopic dermatitisBjorneboe A, Soyland E, Bjorneboe GE, Rajka G, Drevon CA. Journal of Internal Medicine, 1989. PubMed 2650695 →
- Role of the gut microbiota in atopic dermatitis: a systematic reviewPedersen E, Skov L, Thyssen J, Jensen P. Acta Dermato-Venereologica, 2018. PubMed 30085318 →
- Emollients and moisturisers for eczemavan Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Cochrane Database of Systematic Reviews, 2017. PubMed 28166390 →
Transparency
View edit historyEvery change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.